Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

Rhea-AI Summary

Eton Pharmaceuticals (Nasdaq: ETON) announced it will report third quarter 2025 financial results on Thursday, November 6, 2025. Management will host a conference call and live audio webcast at 4:30 p.m. ET (3:30 p.m. CT) to discuss results and take live and emailed investor questions.

Investors may submit questions to investorrelations@etonpharma.com. The live webcast is available on the company investor website at https://ir.etonpharma.com/. An archived webcast will be posted approximately two hours after the event and remain available for 30 days.

DEER PARK, Ill., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).

Participant Call Link:	Click Here
Webcast:	Click Here

In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.

The live webcast can also be accessed on the Investors section of Eton’s website at https://ir.etonpharma.com/. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.

About Eton Pharmaceuticals

Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has eight commercial rare disease products: KHINDIVI™, INCRELEX^®, ALKINDI SPRINKLE^®, GALZIN^®, PKU GOLIKE^®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has five additional product candidates in late-stage development: ET-600, Amglidia^®, ET-700, ET-800 and ZENEO^® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.

Investor Relations:

Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

Source: Eton Pharmaceuticals, Inc.

FAQ

When will Eton Pharmaceuticals (ETON) release its Q3 2025 results?

Eton will report third quarter 2025 results on Thursday, November 6, 2025.

What time is the ETON Q3 2025 earnings call and webcast?

The conference call and live webcast start at 4:30 p.m. ET (3:30 p.m. CT) on November 6, 2025.

How can investors join the ETON Q3 2025 webcast?

Access the live webcast via the Investors section at https://ir.etonpharma.com/ or the provided webcast link.

Can investors submit questions before Eton's November 6, 2025 call?

Yes. Investors may email questions to investorrelations@etonpharma.com ahead of or during the call.

When will the Eton (ETON) webcast be available on demand after the call?

An archived webcast will be posted about two hours after the event and remain available for 30 days.

Will Eton discuss financial results and take live questions on the November 6, 2025 call?

Yes. Management will discuss Q3 2025 financial results and take live and emailed investor questions during the call.